Transcriptomics

Dataset Information

0

Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer


ABSTRACT: Group 3 innate lymphoid cells (ILC3s) are critical regulators of intestinal homeostasis, yet their role in cancer remains elusive. Here, we identify that the tumor microenvironment of humans and mice with colorectal cancer (CRC) contains altered ILC3 responses that resemble those found during intestinal inflammation and are characterized by reduced frequencies, altered subset distribution, and an imbalance with T cells. We evaluated the consequences of these changes in mice and determined that ILC3-specific major histocompatibility complex class II (MHCII) was required to limit the progression of CRC. Interestingly, ILC3-specific MHCII also prevented resistance to anti-PD-1 immunotherapy by regulating intestinal inflammation and microbiota composition. Finally, humans with intestinal inflammation and dysregulated ILC3s also harbor specific microbiota that are sufficient to promote immunotherapy resistance in mice. Collectively, these data define a protective role for antigen-presenting ILC3s in cancer, and indicate that inherent disruption of this pathway drives CRC progression and immunotherapy resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE165814 | GEO | 2021/07/09

REPOSITORIES: GEO

Similar Datasets

2018-12-26 | GSE120723 | GEO
2022-08-31 | GSE168079 | GEO
2022-08-31 | GSE168077 | GEO
2022-08-31 | GSE168076 | GEO
2022-09-08 | GSE212590 | GEO
2022-08-31 | GSE168078 | GEO
2015-11-23 | E-GEOD-71198 | biostudies-arrayexpress
2018-06-29 | E-MTAB-6639 | biostudies-arrayexpress
2019-11-18 | GSE136171 | GEO
2020-03-17 | GSE114750 | GEO